PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 24, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Hereditary Angioedema
Interventions
DRUG

KVD900 600 mg

KVD900 Tablet 600 mg (2 x 300 mg)

DRUG

Drug: KVD900 300 mg

KVD900 Tablet 300 mg

Trial Locations (61)

1023

KalVista Investgative Site, Auckland

1090

KalVista Investigative Site, Vienna

1431

KalVista Investigative Site, Sofia

2560

KalVista Investigative Site, Campbelltown

7700

KalVista Investigative Site, Cape Town

11521

KalVista Investigative Site, Athens

11527

KalVista Investigative Site, Athens

12203

KalVista Investigative Site, Berlin

17033

Kalvista Investigative Site, Hershey

20815

KalVista Investigative Site, Chevy Chase

28046

KalVista Investigative Site, Madrid

28277

KalVista Investigative Site, Charlotte

31048

KalVista Investigative Site, Haifa

38043

KalVista Investigative Site, Grenoble

40215

KalVista Investigative Site, Louisville

43617

KalVista Investigative Site, Toledo

45236

KalVista Investigative Site, Cincinnati

47715

KalVista Investigative Site, Evansville

52621

KalVista Investigative Site, Ramat Gan

55131

KalVista Investigative Site, Mainz

55446

KalVista Investigative Site, Plymouth

59037

KalVista Investigative Site, Lille

60590

KalVista Investigative Site, Frankfurt

63141

KalVista Investigative Site, St Louis

64239

KalVista Investigative Site, Tel Aviv

64546

KalVista Investigative Site, Mörfelden-Walldorf

66211

KalVista Investigative Site, Overland Park

72205

KalVista Investigative Site, Little Rock

75012

KalVista Investigative Site, Paris

75231

KalVista Investigative Site, Dallas

80112

KalVista Investigative Site, Centennial

80907

KalVista Investigative Site, Colorado Springs

84041

KalVista Investigative Site, Layton

85251

KalVista Investigative Site, Scottsdale

90404

KalVista Investigative Site, Santa Monica

92122

KalVista Investigative Site, San Diego

92123

KalVista Investigative Site, San Diego

99204

KalVista Investigative Site, Spokane

547530

KalVista Investigative Site, Sângeorgiu de Mureş

4920235

KalVista Investigative Site, Petach Tikvah

H2W 1R7

KalVista Investigative Site, Montreal

002-8072

KalVista Investigative Site, Sapporo

260-8677

KalVista Investigative Site, Chiba

730-8518

KalVista Investigative Site, Hiroshima

350-8550

KalVista Investigative Site, Kawagoe-shi

371-8511

KalVista Investigative Site, Maebashi

340-0041

KalVista Investigative Site, Soka-shi

569-8686

KalVista Investigative Site, Takatsuki-shi

142-8666

KalVista Investigative Site, Tokyo

236-0004

KalVista Investigative Site, Yokohama

1105 AZ

KalVista Investigative Site, Amsterdam

036 59

KalVista Investigative Site, Martin

08035

KalVista Investigative Site, Barcelona

08907

KalVista Investigative Site, Barcelona

B9 5SS

KalVista Investigative Site, Birmingham

CB2 0QQ

KalVista Investigative Site, Cambridge

CF14 4XW

KalVista Investigative Site, Cardiff

GU16 7UJ

KalVista Investgative Site, Frimley

LS9 7TF

KalVista Investigative Site, Leeds

E1 2ES

KalVista Investigative Site, London

NW3 2QG

KalVista Investigative Site, London

Sponsors
All Listed Sponsors
lead

KalVista Pharmaceuticals, Ltd.

INDUSTRY

NCT05511922 - PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial | Biotech Hunter | Biotech Hunter